nach oben

Journal of Neuro-Oncology

Erschienen in:

01.07.2013 | Clinical Study

Correlation between ^99mTc-HYNIC-octreotide SPECT/CT somatostatin receptor scintigraphy and pathological grading of meningioma

verfasst von: Shengjun Wang, Weidong Yang, Jinglan Deng, Jianning Zhang, Fucheng Ma, Jing Wang

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to explore the association of ^99mTc-HYNIC-octreotide SPECT/CT somatostatin receptor scintigraphy (SRS) with the pathological grading and expression of somatostatin receptor 2 (SSTR2) for meningioma, and to define possible roles of SRS in the pathological grading of meningioma. Thirty patients with meningiomas diagnosed by MRI and treated with ^99mTc-HYNIC-octreotide SPECT/CT SRS. Meningioma tissues were obtained from analyzing pathological grading and measuring the expression of SSTR2 with immunohistochemical staining. The meningioma side (T) to the contralateral side (NT) ratios (T/TN) of radioactive counts were calculated to investigate their association with the pathological grading of meningioma and the expression of SSTR2. All 30 cases showed high meningioma radioactivity accumulation using SRS with a sensitivity of 100 %, while CT scans only detected 25 cases with a sensitivity of 83 %. Twenty cases with grade I meningioma had a T/NT ratio of 3.80 ± 1.67, which was significantly lower than the other 10 cases (9.57 ± 3.78) with a grade II meningioma (P < 0.01). All meningiomas expressed SSTR2 as detected by immunohistochemical staining, and the T/NT ratio was positively associated with the pathological grading of meningioma and the expression of SSTR2 (with r of 0.784 and 0.805, respectively). ^99mTc-HYNIC-octreotide SPECT/CT SRS is a sensitive technique for detecting meningioma, and the T/NT ratio of the SRS data closely correlates with the pathological grade of meningioma and the expression of SSTR2.

Black P (1997) Meningiomas. In: Black P, Loeffler JS (eds) Cancer of the nervous systems. Blackwell Science, Oxford, pp 349–362

Jääskeläinen J, Haltia M, Servo A (1986) A typical and anaplastic meningiomas: radiology, surgery, radiotherapy and outcome. Surg Neurol 25:233–242PubMedCrossRef

Perry A, Gutmann DH, Reifenberger G (2004) Molecular pathogenesis of meningiomas. J Neuro-Oncol 70:183–202CrossRef

Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A et al (2006) Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [⁶⁸Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys 65:222–227PubMedCrossRef

Dutour A, Kumar U, Panetta R, Quafik L, Fina F, Sasi R et al (1998) Expression of somatostain receptor subtypes in human brain tumors. Int J Cancer 76:620–627PubMedCrossRef

Durd A, Champier J, Jouvet A, Labrousse F, Honnorat J, Guyotat J, Schulz S et al (2008) Expression of c-myc, neurofibromatosis type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes. Clin Neuropathol 27:334–345

Arena S, Barbieri F, Thaellungi S, Pirani P, Corsaro A, Villa V et al (2004) Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neuro-Oncol 66:155–166CrossRef

Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrandt G, Klug N et al (1998) Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med 25:675–686PubMedCrossRef

Duet M, Sauvaget E, Pételle B, Rizzo N, Guichard JP, Wassef M et al (2003) Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med 44:1767–1774PubMed

10.

Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J et al (2005) Characterization of ⁶⁸Ga-DOTA-D-Phe¹-Tyr³-octreotide kinetics in patients with meningiomas. J Nucl Med 46:763–769PubMed

11.

Haldemann AR, Rosier H, Barth A, Waser B, Geiger L, Godoy N et al (1995) Somatostatin receptor scintigraphy in central nervous system tumors: role of blood–brain barrier permeability. J Nucl Med 36:403–410PubMed

12.

Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A et al (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20(11):1172–1182PubMedCrossRef

13.

Miederer M, Seidl S, Buck A, Scheidhauer K, Wester H-J, Schwaiger M et al (2009) Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68 Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 36:48–52PubMedCrossRef

14.

Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ (2000) ^99mTc-HYNIC-[Tyr³]-octreotide for imaging somatostatin-receptor-positive tumor: preclinical evaluation and comparison with ¹¹¹In-octreotide. J Nucl Med 41:1114–1119PubMed

15.

Nicolato A, Giorgetti P, Foroni R, Grigolato D, Pasquin IP, Zuffante M et al (2005) Gamma knife radiosurgery in skull base meningiomas: a possible relationship between somatostatin receptor decrease and early neurological improvement without tumour shrinkage at short-term imaging follow-up. Acta Neurochir (Wien) 147:367–375CrossRef

16.

Klutmann S, Bohuslavizki KH, Brenner W, Behnke A, Tietje N, Kröger S et al (1998) Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma. J Nucl Med 39:1913–1917PubMed

17.

Schulz S, Pauli SU, Schulz S, Händel M, Dietzmann K, Firsching R et al (2000) Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res 6:1865–1874PubMed

18.

Reubi JC, Waser B, Schaer JC, Laissue JA (2001) Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28:836–846PubMedCrossRef

19.

Schulz S, Helmholz T, Schmitt J, Franke K, Otto HJ, Weise W (2002) The positive somatostatin receptor scintigraphy in primary breast cancer correlates with expression of ss2A and sst5. Breast Cancer Res Treat 72:221–226PubMedCrossRef

20.

Kwekkeboom DJ, Krenning EP (2002) Somatostatin receptor imaging. Semin Nucl Med 32:84–91PubMedCrossRef

21.

Mezi S, Primi F, Orsi E, Capoccetti F, Scopinaro F, Schillaci O (2005) Somatosatin scintigraphy in the metastatic breast cancer patients. Oncol Rep 13:31–35PubMed

22.

Nathoo N, Ugokwe K, Chang AS, Li L, Ross J, Suh JH et al (2007) The role of 111 indium–octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas. J Neuro-Oncol 81:167–174CrossRef

23.

Gabriel M, Hausler F, Bale R, Moncayo R, Decristoforo C, Kovacs P, Virgolinin I (2005) Image fusion analysis of 99mTc-HYNIC-Tyr3-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Eur J Nucl Med 32:1440–1451CrossRef

24.

Hasseleid BF, Meling TR, Rønning P, Scheie D, Helseth E (2012) Surgery for convexity meningioma: Simpson grade I resection as the goal: clinical article. J Neurosurg 117(6):999–1006PubMedCrossRef

25.

Willis J, Smith C, Ironside J, Erridge S, Whittle I, Everington D (2005) The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol Appl Neurobiol 31:141–149PubMedCrossRef

26.

Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20:1172–1182PubMedCrossRef

27.

Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger M et al (2009) Correlation of immunohistopathological expression of somatostatin receptor-2 with standardized uptake values in 68 Ga-DOTATOC PET/CT. Eur J Nucl Med 36:48–52CrossRef

Titel: Correlation between 99mTc-HYNIC-octreotide SPECT/CT somatostatin receptor scintigraphy and pathological grading of meningioma
verfasst von: Shengjun Wang
Weidong Yang
Jinglan Deng
Jianning Zhang
Fucheng Ma
Jing Wang
Publikationsdatum: 01.07.2013
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2013
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-013-1146-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Suicide ideation in pediatric and adult survivors of childhood brain tumors

BRAF alterations in pediatric low grade gliomas and mixed neuronal–glial tumors

Blood-based biomarkers for malignant gliomas

Vemurafenib and radiation therapy in melanoma brain metastases

Histopathological correlates with survival in reoperated glioblastomas

Brain metastatic volume and white matter lesions in advanced cancer patients